On Wednesday, Cuban scientists report results from Phase II clinical trials of HEBERSaVax, a therapeutic vaccine candidate based on active immunotherapy designed to treat various solid tumors. President Miguel Díaz-Canel presided over the meeting at the Palace of the Revolution, where the technical indicators of the Cuban biotechnology project were detailed.

RELATED:

Cuba Denounces Reports of Possible U.S. Military Action

The drug operates through active immunotherapy with multiple functions. Dr. Yanelys Morera Díaz, a leading scientist and full member of the Cuban Academy of Sciences, explained that the product interferes with tumor nutrition and oxygenation mechanisms, generates specific antibodies that interrupt blood flow to the cancerous mass, and restores the patient’s immune response to eliminate malignant cells. This technical configuration distinguishes it as a unique development of its kind globally.

The research has passed the relevant regulatory stages, progressing from preclinical trials in animal models to Phase II clinical studies focused on specific locations.

The data collected confirm that patients experienced measurable improvements in their quality of life, with adverse effects classified as few and tolerable.

Morera Díaz indicated that these characteristics allow “this candidate to be combined even with conventional therapies, without increasing toxicity,” facilitating its use in established treatment regimens.

The text reads, “The Cuban Foreign Affairs Ministry presented statistical charts to the UN Security Council that highlight the impact of the U.S. blockade on the significant deterioration of Cuba’s child health indicators, specifically the ‘Mortality Rate’ and ‘Prospects for Children with Cancer’.”

Clinical researcher Julio Hernández confirmed that HEBERSaVax has a high safety profile and projected its applicability in many solid tumors, as it has high expression of the protein that promotes tumor growth and spread.

For her part, specialist Adriana Felinciano Pozo corroborated the consistency of the indicators and explained that its administration is subcutaneous, which optimizes clinical logistics. The studies validate oncological responses in colorectal cancer, hepatocellular carcinoma, ovarian cancer, and renal cancer.

Given the global incidence of cancer as a leading cause of death, the scientific team and health authorities plan to continue the research phases of HEBERSaVax to integrate it into the available therapeutic arsenal.

The presentation took place within the framework of the meeting of Experts and Scientists on Health Issues, where the eligibility criteria and roadmap for advancing the drug to the next stages of regulatory validation were evaluated.

IN THIS ARTICLE